Xia Han

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Elena J. Orlando, Xia Han, Catherine Tribouley et al. · Nature Medicine · 2018 · 567 citations

Life Sciences, Genetics, Oncology +17

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Karen Thudium Mueller, Shannon L. Maude, David L. Porter et al. · Blood · 2017 · 359 citations · Full text

Medicine, Oncology, Pharmacology +13

PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial

Martin H. Voss, Albert Reising, Mahtab Marker et al. · Clinical Cancer Research · 2018 · 38 citations

Medicine, Genetics, Oncology +17

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

Jason R. Westin, Constantine S. Tam, Peter Borchmann et al. · Blood · 2019 · 33 citations

Medicine, Hematology, Oncology +13